DK3121280T3 - Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents

Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf

Info

Publication number
DK3121280T3
DK3121280T3 DK16187284.1T DK16187284T DK3121280T3 DK 3121280 T3 DK3121280 T3 DK 3121280T3 DK 16187284 T DK16187284 T DK 16187284T DK 3121280 T3 DK3121280 T3 DK 3121280T3
Authority
DK
Denmark
Prior art keywords
production
methods
antisense compositions
antisense
compositions
Prior art date
Application number
DK16187284.1T
Other languages
English (en)
Inventor
Sergio Baroni
Salvatore Bellinvia
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Application granted granted Critical
Publication of DK3121280T3 publication Critical patent/DK3121280T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DK16187284.1T 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf DK3121280T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425727 2008-11-13
US15229709P 2009-02-13 2009-02-13
EP09756431.4A EP2364360B1 (en) 2008-11-13 2009-11-13 Antisense compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
DK3121280T3 true DK3121280T3 (da) 2025-06-30

Family

ID=42101499

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16187284.1T DK3121280T3 (da) 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK09756431.4T DK2364360T3 (da) 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09756431.4T DK2364360T3 (da) 2008-11-13 2009-11-13 Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf

Country Status (23)

Country Link
US (7) US8912154B2 (da)
EP (2) EP2364360B1 (da)
JP (7) JP5719776B2 (da)
KR (2) KR101767145B1 (da)
CN (2) CN102216458B (da)
AU (4) AU2009315898B2 (da)
CA (2) CA3085272A1 (da)
CY (1) CY1119140T1 (da)
DK (2) DK3121280T3 (da)
ES (2) ES2627745T3 (da)
FI (1) FI3121280T3 (da)
HR (2) HRP20250744T1 (da)
HU (2) HUE032368T2 (da)
LT (2) LT2364360T (da)
MX (3) MX346335B (da)
NZ (1) NZ592673A (da)
PL (2) PL2364360T3 (da)
PT (2) PT3121280T (da)
RS (2) RS56049B1 (da)
RU (2) RU2593939C2 (da)
SI (2) SI3121280T1 (da)
SM (2) SMT202500239T1 (da)
WO (1) WO2010054826A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
ITCO20120008A1 (it) * 2012-03-01 2013-09-02 Nuovo Pignone Srl Metodo e sistema per monitorare la condizione di un gruppo di impianti
CN104487574B (zh) * 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US20140122184A1 (en) * 2012-10-29 2014-05-01 Elwha Llc Food Supply Chain Automation Grocery Information System And Method
US20150335763A1 (en) * 2013-01-09 2015-11-26 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2970419B8 (en) * 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
US20170247695A1 (en) 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP6583954B2 (ja) * 2015-01-08 2019-10-02 日東電工株式会社 展示装置および映像展示方法
WO2016130832A1 (en) * 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
AU2016360956A1 (en) 2015-11-25 2018-06-07 Nogra Pharma Limited IL-34 antisense oligonucleotides and methods of using same
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
US20190046490A1 (en) 2016-02-26 2019-02-14 Nogra Pharma Limited Methods of treating lactose intolerance
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
WO2020152350A1 (en) 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
EP3921299B1 (en) 2019-02-08 2024-11-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
MX2021010255A (es) 2019-02-26 2021-12-15 Nogra Pharma Ltd Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.
CN114729363A (zh) 2019-11-15 2022-07-08 诺格拉制药有限公司 Il-34反义剂及其使用方法
CN115552005A (zh) * 2020-04-24 2022-12-30 诺格拉制药有限公司 Smad7反义寡核苷酸(aso)的组合物及其使用方法
CN117321206A (zh) 2021-05-17 2023-12-29 诺格拉制药有限公司 Il-34反义剂及其使用方法
EP4441224A4 (en) 2021-12-03 2026-03-11 Quralis Corp Antisense oligonucleotides with modified skeletal chemicals
JP2026513538A (ja) 2023-03-28 2026-04-28 ノグラ ファーマ リミテッド 回腸嚢炎を処置するためのｓｍａｄ７阻害性アンチセンスオリゴヌクレオチド（ａｓｏ）およびそれを使用する方法
WO2026080323A1 (en) 2024-10-09 2026-04-16 Quralis Corporation Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
DE69433817T2 (de) 1993-09-24 2005-07-14 Advanced Immuni T, Inc. Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998049348A1 (en) 1997-04-30 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced bioavailability
IE970794A1 (en) * 1997-09-24 2000-08-23 Elan Corp Plc Composition and method for enhancing paracellular transport across cell layers
US7341741B1 (en) 1997-09-26 2008-03-11 Jean-Pierre Sachetto Pharmaceutical composition for the treatment of inflammatory bowel disease
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
CA2329130A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ZA200502318B (en) * 2002-10-16 2006-11-29 Takeda Pharmaceutical Controlled release preparation
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
PT2446881E (pt) * 2003-07-24 2014-06-11 Glaxosmithkline Llc Películas de dissolução oral
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
RU2375047C2 (ru) 2004-03-26 2009-12-10 Лек Фармасьютиклз Д.Д. Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
WO2006056078A1 (en) 2004-11-26 2006-06-01 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
CN101151035A (zh) * 2004-12-02 2008-03-26 Isis制药公司 用于治疗炎性肠病的治疗性反义寡核苷酸组合物
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
WO2007016350A2 (en) 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007047553A2 (en) 2005-10-14 2007-04-26 Zweig Jack I Methods and compositions for treatment of prostate intraepithelial neoplasia
CN1850135A (zh) * 2006-03-09 2006-10-25 陈世忠 一种鸦胆子油肠溶软胶囊制剂及其制备方法和其应用
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
ES2627745T3 (es) * 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9364495B2 (en) * 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
EP2970419B8 (en) 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
EP3174895A1 (en) 2014-07-28 2017-06-07 Nogra Pharma Limited Methods and compositions for diagnosing and treating inflammatory bowel disorders
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
JP2019507755A (ja) 2016-02-24 2019-03-22 ノグラ ファーマ リミテッド Ｓｍａｄ７阻害を使用するセリアック病の処置の方法
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
KR20110086599A (ko) 2011-07-28
CN102216458B (zh) 2017-05-24
MX346335B (es) 2017-03-14
PT2364360T (pt) 2017-06-27
US20150232854A1 (en) 2015-08-20
JP2012508705A (ja) 2012-04-12
EP3121280A1 (en) 2017-01-25
EP2364360B1 (en) 2017-03-22
ES2627745T3 (es) 2017-07-31
MX2023008408A (es) 2023-10-19
JP5719776B2 (ja) 2015-05-20
JP7377624B2 (ja) 2023-11-10
US20120015033A1 (en) 2012-01-19
US20160222383A1 (en) 2016-08-04
PL2364360T3 (pl) 2017-09-29
LT3121280T (lt) 2025-07-25
ES3034412T3 (en) 2025-08-18
SI3121280T1 (sl) 2025-08-29
DK2364360T3 (da) 2017-06-19
AU2017279624B2 (en) 2020-02-06
HRP20170926T1 (hr) 2017-09-22
HRP20250744T1 (hr) 2025-08-15
HUE032368T2 (en) 2017-09-28
AU2009315898A1 (en) 2010-05-20
LT2364360T (lt) 2017-08-10
RU2016127232A (ru) 2018-12-06
US9982264B2 (en) 2018-05-29
NZ592673A (en) 2013-01-25
JP2015232039A (ja) 2015-12-24
US10272047B2 (en) 2019-04-30
AU2015246097B2 (en) 2018-01-18
US20190374472A1 (en) 2019-12-12
CA2743329A1 (en) 2010-05-20
CN102216458A (zh) 2011-10-12
FI3121280T3 (fi) 2025-07-02
CN107007616A (zh) 2017-08-04
JP2017075184A (ja) 2017-04-20
US20210290656A1 (en) 2021-09-23
US8912154B2 (en) 2014-12-16
WO2010054826A1 (en) 2010-05-20
RU2593939C2 (ru) 2016-08-10
JP2014196356A (ja) 2014-10-16
JP6530772B2 (ja) 2019-06-12
RU2739302C2 (ru) 2020-12-22
KR101767145B1 (ko) 2017-08-11
HUE071668T2 (hu) 2025-09-28
SMT201700346T1 (it) 2017-09-07
AU2009315898B2 (en) 2015-07-23
AU2015246097A1 (en) 2015-11-12
US20170107520A1 (en) 2017-04-20
US9314434B2 (en) 2016-04-19
US9499819B2 (en) 2016-11-22
CA3085272A1 (en) 2010-05-20
SMT202500239T1 (it) 2025-09-12
US20150125523A1 (en) 2015-05-07
RU2011123876A (ru) 2012-12-20
KR101921014B1 (ko) 2018-11-21
RS56049B1 (sr) 2017-09-29
JP2021138778A (ja) 2021-09-16
JP2023138750A (ja) 2023-10-02
JP6095744B2 (ja) 2017-03-15
RU2016127232A3 (da) 2019-12-18
CA2743329C (en) 2020-09-01
CY1119140T1 (el) 2018-02-14
SI2364360T1 (sl) 2017-08-31
PL3121280T3 (pl) 2025-09-01
AU2017279624A1 (en) 2018-01-18
RS66973B1 (sr) 2025-07-31
JP2019151658A (ja) 2019-09-12
KR20170092719A (ko) 2017-08-11
EP3121280B1 (en) 2025-04-09
EP2364360A1 (en) 2011-09-14
AU2020202813A1 (en) 2020-05-21
PT3121280T (pt) 2025-07-01
MX2011005042A (es) 2011-08-17

Similar Documents

Publication Publication Date Title
BRPI0920284A2 (pt) composição e método
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
BRPI0919575A2 (pt) método, e, composição
EP2313553A4 (en) Artificial stone
DK2272339T3 (da) Fremgangsmåder og præparater til anvendelse med geldispensere
EP3988147C0 (en) INSERT SET
UA18940S (uk) Шоколад
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
BRPI0823277A2 (pt) Composição, e , método
BRPI0809573A8 (pt) composição, e, método
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
BRPI0917231A2 (pt) composição
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0814167A2 (pt) Composição, e, método
BRPI1006996A2 (pt) composição, método e uso
BRPI0823238A2 (pt) Composição, e, método
BRPI0809678A2 (pt) Métodos
BRPI0909634A2 (pt) 2-aminoquinolinas
DK2334596T3 (da) Ferriphosphatbaseret sammensætning og anvendelse heraf
DK2262525T3 (da) Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme
FI20075086A0 (fi) Aromikoostumus